{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008208","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.287020+00:00","generated_at":"2026-06-01T23:10:34.466008+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptimmune secures up to $125M term loan facility with Hercules Capital","bullets":["First tranche of $25M available upon closing; additional $25M eligible upon afami-cel FDA approval.","Three more tranches totaling $75M available subject to performance milestones and lender discretion.","Interest rate is greater of 9.65% or Prime+1.15%; maturity date is June 1, 2029.","Prepayment premium of 3%-1% sliding scale; end-of-term charge of 5.85% of principal.","Loan secured by substantially all assets including IP; financial covenant requires minimum Qualified Cash from Jan 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008208","json":"https://secwatch.observer/filing/0001558370-24-008208.json","markdown":"https://secwatch.observer/filing/0001558370-24-008208.md","text":"https://secwatch.observer/filing/0001558370-24-008208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024008208/0001558370-24-008208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024008208/adap-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:10:34.466008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7458bbd81611821493a466484aecef9583fc15ed","claim":"Adaptimmune Therapeutics PLC incurred credit facility of up to $125.0 million with Hercules Capital, Inc. at an annual rate equal to the greater of (i) 9.65% or (ii) 1.15% plus the Wall Str maturing June 1, 2029.","evidence_excerpt":"On May 14, 2024 (the “Closing Date”), Adaptimmune Therapeutics plc (the “Company” and collectively with any Company affiliates that are made party to the Loan Agreement, “Borrower”) entered into a Loan and Security Agreement (the “Loan Agreement”), with several banks and other financial institutions or entities from time to time party hereto as lenders (each, a “Lender”, and collectively “Lenders”) and Hercules Capital, Inc., a Maryland corporation in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, including any successors or assigns, the “Agent”), for a term loan facility of up to $125.0 million (the “Term Loan”), consisting of a term loan advance in the aggregate principal amount equal to $25.0 million on the Closing Date (the “Tranche 1 Advance”), a term loan advance available to the Company subject to certain terms and conditions in the aggregate principal amount of $25.0 million (the “Tranche 2 Advance’), a term loan advance","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024008208/0001558370-24-008208-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $125.0 million"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Rate","value":"an annual rate equal to the greater of (i) 9.65% or (ii) 1.15% plus the Wall Str"},{"label":"Maturity","value":"June 1, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"dcda5b953a6ed7a0afa26979437457429ce19525","claim":"Adaptimmune Therapeutics PLC entered into Loan and Security Agreement with Hercules Capital, Inc. valued at up to $125,000,000 term loan facility (effective 2024-05-14).","evidence_excerpt":"On May 14, 2024 (the “Closing Date”), Adaptimmune Therapeutics plc (the “Company” and collectively with any Company affiliates that are made party to the Loan Agreement, “Borrower”) entered into a Loan and Security Agreement (the “Loan Agreement”), with several banks and other financial institutions or entities from time to time party hereto as lenders (each, a “Lender”, and collectively “Lenders”) and Hercules Capital, Inc., a Maryland corporation in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, including any successors or assigns, the “Agent”), for a term loan facility of up to $125.0 million (the “Term Loan”), consisting of a term loan advance in the aggregate principal amount equal to $25.0 million on the Closing Date (the “Tranche 1 Advance”), a term loan advance available to the Company subject to certain terms and conditions in the aggregate principal amount of $25.0 million (the “Tranche 2 Advance’), a term loan advance","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024008208/0001558370-24-008208-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Value","value":"up to $125,000,000 term loan facility"},{"label":"Effective","value":"2024-05-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}